On air · 1 of 3 networks
Helus Pharma
- helus.com
- Healthcare & Life Sciences
- CA
- 108 employees
Helus Pharma’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 42. Watch Helus Pharma with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 38 | Checked 29 Oct 2026 | See all 42 ads → | ||
| Meta | None recorded | 0 | No active ads recorded on the Meta Ad Library | Checked 21 Oct 2026 | Collect them with the API → |
| Not checked | — |
Helus Pharma has 38 live LinkedIn ads. Its Facebook page had no active ads on 21 Oct 2026.
Latest ads
- LINKEDIN · JOBSince 6 May 2025
- LINKEDIN · IMAGERecorded 22 Sept 2026
Cybin has taken a leadership position in the psychedelic therapeutics space with innovative molecules, optimized delivery, and a best-in-class intellectual property portfolio.
- LINKEDIN · IMAGERecorded 22 Sept 2026
Cybin is pleased to announce a ~$175 million registered direct offering with prominent biotech investors. New and existing investors include: Venrock Healthcare Capital Partners, OrbiMed , Point72 Ventures , Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners, Ally Bridge Group.
- LINKEDIN · IMAGERecorded 22 Sept 2026
Cybin Inc.'s recent Australian approval for their Phase 3 study of CYB003 marks another milestone towards addressing unmet mental health needs. Explore investment opportunities with a company committed to making impactful advancements.
- LINKEDIN · IMAGERecorded 22 Sept 2026
Discover how Cybin Inc. is pioneering advancements in mental health treatment through innovative biotechnology research. Stay informed with our Investor Alerts and be part of this transformative journey.
- LINKEDIN · VIDEORecorded 22 Sept 2026
Approximately 50% of patients with Generalized Anxiety Disorder (GAD) are unresponsive to first line treatment with selective serotonin reuptake inhibitors (“SSRIs”) and serotonin-norepinephrine reuptake inhibitors (“SNRIs”). Learn more about Cybin’s CYB004 currently under evaluation in a Phase 2 study in GAD: https://loom.ly/cG2oYxU
6 of 42 adsSign up to see every Helus Pharma ad, filter by format and date, and get alerts on new ones.
See all 42 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.